Live feed06:59:00·376dPRReleasevia QuantisnowBristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025ByQuantisnow·Wall Street's wire, on your screen.BMY· Bristol-Myers Squibb CompanyHealth Care
